A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Sotagliflozin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms inTandem3
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 13 Sep 2017 Results published in the New England Journal of Medicine
    • 13 Sep 2017 Results published in a Lexicon Pharmaceuticals Media Release.
    • 13 Sep 2017 According to a Lexicon Pharmaceuticals media release, data were presented at European Association for the Study of Diabetes (EASD) 53rd annual meeting and published in the New England Journal of Medicine (NEJM).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top